Beam Therapeutics INC 8-K filings

Beam Therapeutics announced second quarter 2026 financial results, highlighting progress in its AATD, PKU, and SCD programs, with a strong cash runway extending into mid-2029.

Beam Therapeutics Inc. announced the voting results from its 2026 annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

Beam Therapeutics reported Q1 2026 results, highlighting clinical advancements in genetic diseases and hematology, with a strong cash position extending runway to mid-2029.

Beam Therapeutics ensures continued access to critical base editing patent rights through a new direct license with Kobe University following the dissolution of Bio Palette Co., Ltd.

Beam Therapeutics announced a new $500 million financing agreement with Sixth Street, expanded its pipeline with a new PKU program, and reported improved Q4 and full-year 2025 financial results.

Beam Therapeutics entered a standby license agreement with Kobe University and Bio Palette, ensuring continued access to critical gene-editing patents.

Carole Ho has resigned from the Board of Directors of Beam Therapeutics Inc., effective February 27, 2026.

Beam Therapeutics announced an extended operating runway into 2029, supported by $1.25 billion in cash, and significant progress across its genetic disease and hematology programs, including a potential accelerated approval pathway for BEAM-302 and a planned BLA submission for risto-cel.

Beam Therapeutics Inc. announced the completion of Bristol-Myers Squibb's acquisition of Orbital Therapeutics, resulting in $255.1 million in cash proceeds for Beam.

Beam Therapeutics reported third-quarter 2025 financial results, highlighted by clinical progress in its gene editing programs for sickle cell disease and alpha-1 antitrypsin deficiency, and an extended cash runway into 2028.

Beam Therapeutics announced robust second quarter 2025 financial results and significant clinical progress across its gene editing pipeline, extending its cash runway into 2028.

Beam Therapeutics Inc. announced the acquisition of an early-stage life sciences company, involving an upfront issuance of common stock and potential future payments tied to development, clinical, and commercial milestones.

Beam Therapeutics Inc. announced the successful election of Class II directors, ratification of Deloitte & Touche LLP as its independent auditor, and advisory approval of executive compensation at its 2025 annual meeting of stockholders.

Beam Therapeutics announces first patient dosed in BEAM-301 trial, positive data from BEAM-302, and a strong financial position with a cash runway into 2028.

Beam Therapeutics has announced an underwritten offering expected to generate approximately $500 million in gross proceeds to further its precision genetic medicine platform.

Beam Therapeutics reports positive initial safety and efficacy data from its Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD), showcasing the first clinical genetic correction of a disease-causing mutation.

Beam Therapeutics announces its Q4 and full year 2024 financial results, reporting $850.7 million in cash and reiterating anticipated clinical milestones for its gene editing programs.

Beam Therapeutics announced progress across its hematology and genetic disease franchises, including updates on clinical trials and anticipated milestones for 2025, along with an estimated cash balance of $850.7 million.

Beam Therapeutics presented promising clinical data for BEAM-101 in sickle cell disease and preclinical data for its ESCAPE conditioning platform at the American Society of Hematology (ASH) Annual Meeting.

Beam Therapeutics has appointed Sravan K. Emany as its new Chief Financial Officer, effective December 19, 2024, bringing extensive financial and operational experience to the company.

Beam Therapeutics has expanded its board of directors by appointing Chirfi Guindo, a seasoned pharmaceutical executive, effective December 2, 2024.

Beam Therapeutics has released initial clinical data for its BEAM-101 sickle cell disease treatment and BEAM-201 leukemia therapy, along with preclinical data for its ESCAPE platform, to be presented at the American Society of Hematology Annual Meeting.

Beam Therapeutics is advancing its gene editing programs, showcasing positive early clinical data for BEAM-101 in sickle cell disease and preclinical progress with its ESCAPE technology.

Beam Therapeutics announced its third quarter 2024 financial results and provided updates on its clinical programs, including progress in sickle cell disease and alpha-1 antitrypsin deficiency.

Beam Therapeutics reported positive progress in its clinical programs, including FDA clearance for BEAM-301 and advancement in BEAM-101 and BEAM-302 trials, while maintaining a strong cash position.

Beam Therapeutics' Chief Financial Officer, Terry-Ann Burrell, will resign effective August 9, 2024, to join JPMorgan Chase, prompting a search for her successor.

Beam Therapeutics held its 2024 annual meeting of stockholders on June 5, 2024, with all proposals passing including the election of a new director and ratification of the company's accounting firm.

Beam Therapeutics announced progress in its clinical programs, including the completion of dosing for the sentinel cohort of its BEAM-101 sickle cell disease trial, and reported a cash balance of $1.1 billion as of March 31, 2024.

Beam Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting a strong cash position and progress in clinical trials for its gene editing programs.